Evidence Table D-15. Survival outcomes in studies comparing interventions to prevent development of delirium

| Author, year | Population | Intervention group, n | Control group, n | Route of administration | Outcome definition | Median (IQR) days, intervention group | Median (IQR), days, control group | Difference in Medians (95% CI) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| First-generation antipsychotic vs. placebo |  |  |  |  |  |  |  |  |
| van den Boogaard, 2018[15](#_ENREF_15) | ICU patients at high risk of delirium | Haloperidol (Planned dose: 1mg), 350 | Placebo (Planned dose: 0.9% NaCl), 707 | Intravenous | Median number of days patients survived at the time of 28 days assessment | 28 (28 to 28) | 28 (28 to 28) | 0 (0 to 0) |
| van den Boogaard, 2018[15](#_ENREF_15) | ICU patients at high risk of delirium | Haloperidol (Planned dose: 2mg), 732 | Placebo (Planned dose: 0.9% NaCl), 707 | Intravenous | Median number of days patients survived at the time of 28 days assessment | 28 (28 to 28) | 28 (28 to 28) | 0 (0 to 0) |
| van den Boogaard, 2018[15](#_ENREF_15) | ICU patients at high risk of delirium | Haloperidol (Planned dose: 1mg), 350 | Placebo (Planned dose: 0.9% NaCl), 707 | Intravenous | Median number of days patients survived at the time of 90 days assessment | 90 (90 to 90) | 90 (90 to 90) | 0 (0 to 0) |
| van den Boogaard, 2018[15](#_ENREF_15) | ICU patients at high risk of delirium | Haloperidol (Planned dose: 2mg), 732 | Placebo (Planned dose: 0.9% NaCl), 707 | Intravenous | Median number of days patients survived at the time of 90 days assessment | 90 (90 to 90) | 90 (90 to 90) | 0 (0 to 0) |

CI=confidence interval; ICU=intensive care unit; IQR=interquartile range; Mg/hr=milligram per hour; mg=milligram; MV=mechanical ventilation; n=sample size; NaCl=sodium chloride